Pre-Conference Workshop Day
Tuesday, November 12 2024
7:00 am Check in, Morning Coffee & Light Breakfast
Workshop A
8:00 am Hidradenitis Suppurativa: An Evolving Drug Development Landscape
Synopsis
Join us for a comprehensive workshop on the opportunities for therapeutic development for Hidradenitis Suppurativa, a disease with increasingly realized prevalence and epidemiologic links to further autoimmune, metabolic and clinically relevant diseases. Explore challenges faced in the development of therapeutics addressing a high disease burden, as well as recent pipeline advancements and strategies which are revealing the potential for innovative approaches improving the therapeutic options for patients.
Participate to uncover:
- The current understanding of Hidradenitis Suppurativa pathophysiology and unmet needs in drug development
- Emerging therapeutic targets and treatment modalities, as well as promising candidates under development
- Opportunities to optimize clinical trial design and patient recruitment
Leverage this session to uncover the therapeutic landscape and opportunities for achieving clinical efficacy superiority.
10:00 am Morning Break
Workshop B
10:30 am Everyone Is Talking About JAK Inhibitors: Addressing Safety in Dermatology
Synopsis
As JAK inhibitors bring a level of efficacy unseen previously for Atopic Dermatitis, and Incyte’s Phase II in Hidradenitis Suppurativa reinforce the safety of the selective JAK1/ JAK2 inhibitor topical cream, is this enough to overcome the black box warning of 2021, or are dermatologists still wary of using this modality due to safety concerns?
This workshop will gather experts to discuss:
- As the JAK inhibitor pipeline grows, what dermatology-specific challenges need to be overcome?
- How are toxicity concerns being addressed, and is this impacting access to potential interventions with superior efficacy?
- How do dermatologists view JAK inhibitors and their place in inflammatory disease treatment paradigms?
Gain many stakeholder perspectives, as this workshop presents an evolving therapeutic landscape, and projections for the future role of JAK inhibitors, for improving long-term patient outcomes in dermatology.
Featuring a Case Study from Lynk Pharmaceuticals: Efficacy & Safety of LNK01001 in Chinese Patients with Moderate to Severe Atopic Dermatitis: Results from a 12-week Phase 2 Trial – Download the Event Guide to Learn More.
12:30 pm Lunch & Networking
Workshop C
1:30 pm Developing Multipurpose Drugs: Uncovering Opportunities for Developing a Robust Pipeline Across Dermatology & Beyond
Synopsis
With shared disease pathogenesis mechanisms across dermatological diseases with immune-inflammatory drivers, in addition to indications beyond in GI, Rheumatology and autoimmune disease groups, which indications are the next for biopharma to target and leverage the success? Through being able to demonstrate therapeutic potential across a broader range on indications, the commercial potential of pipelines is multiplied.
Leverage this workshop to uncover:
- Identifying inflammatory targets with therapeutic significance across multiple disease
- Realizing efficiency benefits across the drug development timeline, across safety, pharmacology, toxicity, manufacturing and formulation within multipurpose therapeutic development strategy approaches
- Strategizing for fast-tracked drug development, through identifying unmet medical need across indications and opportunities for fast-track designation
Participate to develop a comprehensive strategic roadmap, guiding you through the intricacies of developing a multipurpose inflammatory drug development strategy that is commercially attractive for investment opportunities.
Workshop D
3:30 pm Patient Recruitment in Rare Disease & Competitive Drug Development Landscapes: Enhancing Efficiency & Shortening Timelines to Clinical Development
Synopsis
The dermatological drug development field is expanding fast, with a growing pipeline of therapies targeting disease, both high in prevalence, in addition to pathogenesis insights driving progress for rarer disease populations. With therapeutic breakthroughs for patients on the horizon, this workshop provides a crucial platform to address bottlenecks around recruitment, in order to meet needed regulatory requirements.
Join for a comprehensive picture of:
- Barriers facing clinical recruitment in dermatology, to proactively develop recruitment strategies with these in mind
- Uncover innovative clinical trial design, with cost-strategies enabling the efficient use of limited resources
- Define PRO’s effectively aligned with outcome measures, to build a strong data package for regulatory approval
Gain insight to develop strong and agile clinical develop plans, and use peer-to-peer feedback to bring actionable takeaways for fast-tracking your studies towards regulatory approval.